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AbstrAct
Introduction Although previous conventional meta-analyses 
and network meta-analyses have provided some important 
findings about pharmacological treatments for children and 
adolescents with depressive disorders in the past decades, 
several questions still remain unsolved by the aggregate 
data from those meta-analyses. Individual participant data 
meta-analysis (IPD-MA) enables exploration of the impacts 
of individual characteristics on treatment effects, allowing 
matching of treatments to specific subgroups of patients. We 
will perform an IPD-MA to assess the efficacy and tolerability 
of new-generation antidepressants for major depressive 
disorder in children and adolescents.
Methods and analysis We will systematically search 
for all double-blind randomised controlled trials (RCTs) 
that have compared any new-generation antidepressant 
with placebo for the acute treatment of major depressive 
disorder in children and adolescents, in the following 
databases: PubMed, EMBASE, the Cochrane Library, 
PsycINFO, Web of Science, CINAHL, LILACS and ProQuest 
Dissertations. We will contact all corresponding authors 
of included RCTs and ask for their cooperation in this 
project by providing individual participant data from the 
original trials. The primary outcomes will include efficacy, 
measured as the mean change of depression symptoms by 
Children’s Depression Rating Scale Revised (CDRS-R), and 
tolerability, measured as the proportion of patients who 
withdrew from the trials early due to adverse effects. The 
secondary outcomes will include response rates, remission 
rates, deterioration rate, all-cause discontinuation, 
suicidal-related outcomes and global functioning outcome. 
Using the raw de-identified study data, we will use  
mixed-effects logistic and linear regression models to 
perform the IPD-MAs. The risk of bias of included studies 
will be assessed using the Cochrane risk of bias tool. We 
will also detect the publication bias and effects of  
non-participation of eligible studies.
Dissemination Ethical approval is not required given 
that informed consent has already been obtained from 
the patients by the trial investigators before the included 
trials were conducted. This study may have considerable 
implications for practice and help improve patient care.
PrOsPErO registration number CRD42016051657.
bAckgrOunD 
Major depressive disorder (MDD) is a 
commonly occurring serious mental disorder, 
accounting for a large portion of the global 
burden of disease. The overall prevalence 
rate of depressive disorder is about 3% in 
children and 6% in adolescents.1 Depressive 
disorder in youth is often associated with high 
rates of comorbid mental disorders, func-
tional impairment and suicide.2–5 For young 
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Protocol
strengths and limitations of this study
 ► The study will use individual patient data that can 
take into account within-study and between-study 
differences  and yield more reliable estimates of 
treatment effects than meta-analysis of aggregate 
data.
 ► Individual patient data meta-analysis can provide 
insight into the patient groups most likely to benefit 
from new-generation antidepressants and the most 
effective kinds of antidepressants.
 ► It is difficult to ensure all trials were identified 
because not all trials are registered, especially for 
these old trials.
 ► The another difficulty of this study will be collecting 
the patient-level information from all eligible trials, 
for some of the original investigators may not be 
willing or able to share the data. For example, for the 
fluoxetine trials, European Medicines Agency did not 
have them and Medicines and Healthcare Products 
Regulatory Agency were to have saved the records 
but they could only find three placebo controlled 
double blind randomised controlled trials; the other 
records had been destroyed as per their policy of 
older reports.
 ► We found that different clinical study report (CSRs) 
depending on the company and the time of the study 
varied significantly with respect to quality. Therefore, 
this definitely data would rely on getting access to 
databases, among others, for complete data. 
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people aged 10–19 years, depressive disorders are the 
leading cause of health-related burden, accounting for 
6%–10% of the disability-adjusted life-years.6 Early-onset 
depression is an important predictor of the recurrence of 
depressive disorders. In a naturalistic follow-up study, up 
to 55% paediatric patients who recovered from the first 
episode of MDD had a second episode within 5 years and 
rose to 72% within 15 years.7 
In the past 20 years, several new-generation antidepres-
sants have been found to be effective in the treatment of 
adult MDD.8 9 However, whether to use antidepressants 
in children and adolescents are still matters of contro-
versy, mainly due to concerns about efficacy and poten-
tially increased risk of treatment-emergent suicide in 
those young patients.10 11 In 2004, some worrying inter-
pretations from a conventional meta-analysis were shown: 
published data suggested a favourable risk benefit profile 
for some selective serotonin reuptake inhibitors (SSRIs); 
however, addition of unpublished data indicated that 
risks could outweigh the benefits of these drugs (except 
fluoxetine) for the treatment of depression in children 
and young people.12 Recently, our published network 
meta-analysis showed that most currently available anti-
depressants do not seem to offer a clear advantage over 
placebo for depression in children and adolescents, and 
fluoxetine is probably the best option to consider when 
a pharmacological treatment is indicated.13 Neverthe-
less, several questions still remain unsolved by the aggre-
gate data from conventional and network meta-analyses. 
First, the effect sizes of some antidepressants in previous 
meta-analyses had large confidence/credible interval 
with its upper limit close to the point of no difference, 
which raises the question of whether this estimate is 
robust enough to inform clinical practice.14 Second, most 
studies included both children and adolescents, but they 
did not separately report the data of different age groups. 
Thus, it remains unclear whether the antidepressants 
are efficacious across the diverse populations included. 
Third, there was a strict range of baseline severity scores 
included in these previous meta-analyses. For example, 
in our previous network meta-analysis (NMA) analysis, 
most studies focused on samples with moderate to severe 
depressive severity, with few trials of those with mild to 
moderate or very severe range. Therefore, whether the 
antidepressants have similar efficacy for mildly or severely 
depressed patients is another important question that 
remains. Fourth, RCTs evaluating antidepressant treat-
ments in children and adolescents seldom report the 
number of patients who deteriorated during treatment; 
thus, it is not possible to investigate mean deteriora-
tion effects found in randomised trials and its moder-
ators using conventional and network meta-analytical 
approaches.
Individual participant data meta-analysis (IPD-MA) is 
an increasingly popular approach for synthesising and 
investigating treatment effect estimates. IPD-MA has 
many statistical and clinical advantages over meta-analyses 
of aggregate data. For example, clinical heterogeneity 
can be reduced by controlling for patient-level covari-
ates in IPD-MA,15 16 which offers the potential to explore 
additional, more thorough and potentially more appro-
priate analyses compared with those possible with aggre-
gate data.17 IPD-MA also provides unique opportunities 
to identify underlying individual characteristics as prog-
nostic factors or negative effects across several studies.18 
Therefore, we will perform an IPD-MA to assess the effi-
cacy and tolerability of new-generation antidepressants 
for MDD in children and adolescents.
MEthODs
criteria for included studies
Types of studies
Studies included in this IPD-MA will be double-blind 
randomised controlled trials (RCTs), including studies 
with cluster or cross-over designs. Given possible carry-
over effects, we will only consider data from the first 
study period in cross-over trials. We will exclude trials 
employing inappropriate randomisation strategies, such 
as quasi-randomised designs.
Types of participants
Studies will be included in the IPD-MA if they aim at 
(1) children and adolescents aged between 6 and 18 years 
when initially enrolled in the studies and (2) with primary 
diagnosis of MDD according to standard diagnostic crite-
rion, such as the Diagnostic and Statistical Manual of 
Mental Disorders19–23 or the International Classification 
of Diseases.24 25 Studies will be excluded if they included 
patients with bipolar depression or treatment-resistant 
depression, while patients with comorbid general psychi-
atric disorders, such as anxiety disorder, will not be 
excluded.
Types of interventions
We will include all RCTs comparing any new-generation 
antidepressant with placebo during the acute treat-
ment phase of depression in children and adolescents. 
The following new-generation antidepressants using 
prescribed oral and therapeutic dose range will be 
included.8 13 26
1. SSRIs, for example, fluoxetine, fluvoxamine, paroxe-
tine, sertraline, citalopram and escitalopram.
2. Serotonin and norepinephrine reuptake inhibitors 
(SNRIs), for example, duloxetine, venlafaxine, des-
venlafaxine, milnacipran and levomilnacipran.
3. Other antidepressants, for example, mirtazapine, 
mianserin, nefazodone, trazodone, vortioxetine, vi-
lazodone, bupropion, reboxetine and agomelatine.
We will only include RCTs with a minimum of 4-week 
treatment duration because the onset of benefit for 
most antidepressants often takes at least 4 weeks.27 We 
will exclude trials designed as maintenance treatment or 
relapse prevention, unless outcome data from the acute 
phase can be accessed separately. Combination studies 
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and augmentation studies (eg, combined with different 
antidepressant or psychotherapy) will also be excluded.
Types of outcome measures
Primary outcomes
Overall efficacy: The primary outcome of efficacy will be the 
overall change in depressive symptoms, as measured using 
Children’s Depression Rating Scale Revised (CDRS-R)28 
from baseline to endpoint. For RCTs that didn’t measure 
CDRS-R, we will try to convert other depression scales 
(such as (Hamilton depression scale) HAMD29 or (Mont-
gomery–Åsberg Depression Rating Scale) MADRS)30 
scores to CDRS-R scores, by using a factor derived from 
the RCTs that used both scales.
As shown in our previous network meta-analysis,13 trial 
duration varied from 6 weeks to 36 weeks, and the majority 
of trials employed a treatment duration of 8 weeks. We will 
try to obtain repeated measures from individual trials if 
possible. To improve comparability between the included 
trials, we will prefer the data from 8-week (or the closest 
to 8 week) time point for efficacy outcomes.
Overall tolerability: The tolerability of treatment will be 
the proportion of patients who drop out of the trials early 
due to side effects at the end of the blinded treatment.
Secondary outcomes
Response rate: Response rate will be defined as 50% reduc-
tion from baseline to endpoint on CDRS-R (or another 
standardised rating scale such as HAMD or MADRS).
Remission rate: Remission rate will be defined as the 
CDRS scores of less than 28.31
Deterioration rate: Deterioration represents the depres-
sion symptom severity increases after treatment. Deterio-
ration rate will be defined as the proportion of patients 
whose CDRS-R scores from baseline to endpoint had reli-
able change index below the cut-off of −1.96.32
Overall acceptability: The acceptability of treatment will 
be the proportion of patients who drop out of the trials 
early for any cause at the end of the blinded treatment.
Suicide-related outcomes: Suicide-related dichotomous 
and continuous outcomes will be measured. We will 
extract the number of participants with suicide-related 
events (combined suicidal ideation and suicidal 
behaviour) during the acute treatment, as measured 
on a standardised, validated and reliable rating scale or 
reported cases of suicidal ideation and behaviour.33 In 
addition, if data are available, we will also collect data 
on suicidal ideation as a continuous outcome where a 
standardised, validated and reliable rating scale, such as 
the Suicidal Ideation Questionnaire-Junior High School 
version,34 has been used.
Global functioning: The outcome of global functioning 
will be the overall change in validated scales from base-
line to endpoint. The commonly used tools of func-
tioning scales included the Children’s Global Assessment 
Scale,35 Global Assessment of Functioning36 and so on.
Aggressive behaviour: The outcome of aggressive 
behaviour will be the proportion of cases who reported 
the aggressive behaviour, such as hostility and assault, 
during the acute treatment.37 38
Data sources and search strategy
We will first include the RCTs identified by the criteria 
used in our previous work,13 39 and then we will update 
the extensive searching to bring it up to date. Briefly, we 
will identify any published and unpublished RCTs, in any 
language, from electronic systematic searches of PubMed, 
EMBASE, the Cochrane Library, PsycINFO, Web of 
Science, LILACS, CINAHL and ProQuest Dissertations. 
Electronic databases will be searched with free words 
and Medical Subject Headings terms using the following 
strategy: (depress* or dysthymi* or mood disorder* or 
affective disorder*), combined with (adolesc* or child* 
or boy* or girl* or juvenil* or minors or paediatri* or 
pediatri* or pubescen* or school* or student* or teen* or 
young or youth*) and combined with a list of antidepres-
sants, including (selective serotonin reuptake inhibitors 
or SSRI or fluoxetine or fluvoxamine or paroxetine or 
sertraline or citalopram or escitalopram or serotonin and 
norepinephrine reuptake inhibitors or SNRI or duloxe-
tine or venlafaxine or desvenlafaxine or milnacipran or 
levomilnacipran or mirtazapine or mianserin or nefazo-
done or trazodone or vortioxetine or vilazodone or 
bupropion or reboxetine or agomelatine). In addition, 
we will also identify additional trials and unpublished 
data by searching: (1) international trials registries, 
mainly including of  ClinicalTrials. gov and WHO Inter-
national Clinical Trials Registry Platform; (2) US Food 
and Drug Administration (FDA) reports; (3) the Interna-
tional Prospective Register of Systematic Reviews (PROS-
PERO); (4) websites of main manufactures, for example, 
GlaxoSmithKline, Lilly, Organon, Forest Pharmaceuti-
cals and Bristol-Myers Squibb; (5) manual hand-search 
of key journals and conference proceedings, for example 
J Child Adolesc Psychopharmacol, J Am Acad Child Adolesc 
Psychiatry, Child Adolesc Psychiatry Ment Health, Psychophar-
macol Bull, Arch Gen Psychiatry, Am J Psychiatry, Eur Psychi-
atry and Depress Anxiety. Additional relevant RCTs will be 
obtained by hand-searching reference lists of included 
studies and relevant reviews. We will also contact corre-
sponding authors of included RCTs, manufactures, FDA 
and other possible institutions for unpublished trials.
study selection and data extraction
Selection of trials
We will first manually remove duplicates of initial search 
results, and then two experienced reviewers will inde-
pendently screen titles and abstracts from the retrieved 
results for possible candidates. We will exclude the trials 
in which both reviewers judge they do not meet eligibility 
criteria. Full texts of all remaining papers will be retrieved, 
and two reviewers will independently examine whether to 
include them by the same eligibility criteria. Any differ-
ence of opinion, for each step, between the reviewers will 
be resolved through discussion with another member of 
the reviewing team or by contacting the authors of the 
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trials for clarification. The selection process of retrieved 
studies and the reasons for exclusion of trials (eg, ineli-
gible populations, not randomised trials) will be shown 
in a flow chart.
Data collection
From the included RCTs, two reviewers will independently 
extract the trial level information using standardised data 
collection forms, including trial characteristics, patient 
characteristics, intervention details and any other infor-
mation relevant to this review.
We will contact all corresponding authors or sponsor 
pharmaceutical companies of included RCTs and ask 
for their cooperation in this project. The corresponding 
authors’ contact information will be abstracted from the 
papers, online research profiles (eg, Google Scholar) or 
other available ways. Specifically, we will (1) send emails 
to the authors explaining the study purpose and invite 
them to cooperate in this project; (2) send reminder 
emails 4 and 6 weeks later if no response; and (3) contact 
the corresponding authors by phone or possible personal 
contacts. We will also report on the process of interaction 
with the sponsor companies, as applicable.
Trial-level information and individual participant data 
to be obtained from the original authors are shown in 
table 1, respectively. The raw data can be provided in any 
convenient manner (such as by email) in common types 
of electronic format, such as Excel, SPSS, Stata and so on 
. All obtained data will be converted to a uniform format 
and saved on a secure server at the Chongqing Medical 
University. The data set will not contain any personal 
identifier of patients, such as names or phone numbers. 
Only authorised members of the research team will be 
allowed to access the data set.
Data checking
We will check for data-entry mistakes and consistency and 
reanalyse the data within each study according to the orig-
inal statistical methodology; the results will be compared 
with the published summary results. Any error will be 
resolved by discussion with the original investigators, and 
data corrections will be made if necessary.
Missing data
Handling of missing data will depend on the proportion 
of missing data in the full data set. In general, we will 
prefer to manage missing data for both patient charac-
teristics and outcomes through multiple imputation (MI) 
methods, such as MI and mixed-effects model repeated 
measures (MMRM), because MI techniques with a 
missing at random assumption tends to yield more unbi-
ased results than single imputation methods.40 Missing 
data will be imputed using the command mi impute mvn 
in Stata V.14.0. However, if we obtain repeated measures 
from individual trials, we will use MMRM approach.
risk of bias assessment and quality of study
Two independent review authors will use the Cochrane 
Collaboration’s risk of bias’ tool41 to evaluate the 
methodological and hence bias risk of eligible studies, 
and quality assessment will be reported on a study 
level. The risk of bias will be assessed across seven 
items, including random sequence generation, alloca-
tion concealment, blinding of intervention, blinding of 
outcome assessment, incomplete outcome data, selective 
outcome reporting and other bias (eg, conflicts of inter-
ests) with three levels of risk (high, unclear, low). We will 
rate the quality of study as follows: high-risk study (two 
or more items rated as high risk of bias); low-risk study 
(five or more items rated as low risk and no more than 
one as high risk); unclear risk study (all remaining situ-
ations). Any disagreements will be resolved by consensus 
or consulting the original authors.
Publication bias and effects of non-participation of eligible 
studies
We will use contour enhanced funnel plot to detect publi-
cation bias for study level data (full set of studies meeting 
inclusion criteria) and patient-level data (the set of studies 
that were included in the IPD-MA), if at least 10 studies 
are available.42 We will also use Egger’s test to quantify 
the bias, with a P value <0.10 taken to indicate statistical 
evidence of asymmetry.43 In order to examine the effects 
of non-participation of eligible studies, we will conduct 
a meta-regression analysis with the effect size of primary 
outcomes (based on study level data) as the dependent 
variables and whether or not the patient-level data are 
included as the predictor indicating. The analyses will be 
conducted in Stata V.14.0.
statistical analysis
All analyses will be performed by intention-to-treat anal-
ysis. Descriptive statistics will be presented as mean (SD) 
or median (IQR) for continuous variables and number 
(per cent) for categorical variables.
Individual patient data meta-analyses
We will first use the one-stage approach to perform the 
IPD-MAs, as it offers the highest degree of flexibility for 
making necessary assumptions44 and uses a more exact 
statistical approach than two-stage approach.45 We will 
perform analyses in Stata with the commands mixed (for 
linear random-effects models), meqrlogit (for logistic 
models) and ipdforest (for forest plot).46 To account for 
between study differences, we will use mixed-effects 
logistic models for categorical outcomes and mixed-effects 
linear regression models for continuous outcomes. Treat-
ment assignment will be introduced as a fixed-effects vari-
able ‘treatment’. As outcomes might vary across studies, we 
will force the ‘study’ and the interaction term ‘study*treat-
ment’ as random-effects variables into all models. The 
important clinical and demographic predictors variables 
(eg, sex,47 age,48 baseline severity score49 and treatment 
duration) will be used as regressors in the models. The 
heterogeneity of treatment effects across studies will be 
assessed using the I2 statistic.50 Finally, we will carry out 
the following sensitivity analyses of the primary outcomes: 
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(1) excluding trials with a follow-up longer than 12 weeks 
and (2) excluding studies where HAMD and MADRS 
scores were mapped onto CDRS-R.
Ethics and dissemination
This protocol is registered in PROSPERO at the 
National Health Service Centre for Reviews and Dissem-
ination at the University of York (registration number: 
CRD42016051657). No ethics review is required for 
this IPD-MA, since informed consent has already been 
obtained from the patients by the trial investigators 
before the trial was conducted. We will publish the results 
in a peer-reviewed journal.
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